NBRV | Nabriva Therapeutics PLC
Category: Consumer goods
Quick infos Headquarters: Republic of Ireland Trade prices Volume: Market Cap: 11.38M Prev closed: Open: High: Low: 52 week low: 52 week high: Dividends: Next ER: May 11, 2023
Earnings History Date EPS / Forecast Revenue / Forecast May 11, 2023 March 16, 2023 -4.15 / -4.038.65M / 9.84MNovember 10, 2022 -4.21 / -4.039.15M / 10.68MAugust 3, 2022 -4.5 / -59.19M / 8.53MBeat! May 5, 2022 -0.2 / -0.198.02M / 9.58Mview more
Historical Data Date Price Open High Low Vol Change ER Aug 3, 2022 0.1800 0.1835 0.2100
0.1800
1.17M -0.66% Aug 2, 2022 0.1812 0.1738 0.1845
0.1738
565.21K 6.28% Aug 1, 2022 0.1705 0.1800 0.1828
0.1630
334.24K -4.96% Jul 29, 2022 0.1794 0.1743 0.1800
0.1702
238.19K 1.36% Jul 28, 2022 0.1770 0.1755 0.1780
0.1700
178.46K 0.97% Jul 27, 2022 0.1753 0.1617 0.1754
0.1589
470.53K 5.16% Jul 26, 2022 0.1667 0.1701 0.1701
0.1559
1.45M -3.36% Jul 25, 2022 0.1725 0.1721 0.1730
0.1676
553.08K 0.23% Jul 22, 2022 0.1721 0.1766 0.1789
0.1710
624.79K -2.55% Jul 21, 2022 0.1766 0.1830 0.1830
0.1752
788.46K -2.32% view more
News
Nabriva (NBRV) Aims to Resubmit Contepo NDA in Q4 finance.yahoo.com Dec 11, 2020 5:55 pm
Nabriva Therapeutics Receives U.S. FDA Approval of Xenleta (lefamulin) to Treat Community-Acquired Bacteria Pneumonia (CABP) finance.yahoo.com Dec 11, 2020 3:41 pm
FDA Nods Fuel Unusual Options Volume on NBRV, MRNA finance.yahoo.com Dec 11, 2020 2:40 pm Nabriva Therapeutics prices $15M public offering seekingalpha.com Dec 11, 2020 12:31 pm Nabriva's stock soars after resubmitting NDA for UTI treatment marketwatch.com Dec 11, 2020 6:44 am Nabriva Therapeutics announces proposed public offering seekingalpha.com Dec 11, 2020 5:11 am Analysts Offer Insights on Healthcare Companies: Nabriva (NBRV) and Turning Point Therapeutics (TPTX) smarteranalyst.com Dec 9, 2020 10:53 am About To Invest In Tesla? Consider This Battery Stock Instead nasdaq.com Dec 9, 2020 10:53 am How Risky is Nabriva Therapeutics PLC - ADR (NBRV) Stock? investorsobserver.com Dec 8, 2020 10:53 am Nabriva Therapeutics shares gain as Sinovant expands Xenleta support in China seekingalpha.com Dec 7, 2020 9:09 pm Is Nabriva Therapeutics PLC - ADR (NBRV) Stock a Great Value? investorsobserver.com Dec 4, 2020 10:53 am Nabriva Therapeutics Announces Date of 1-for-10 Reverse ... globenewswire.com Dec 4, 2020 10:53 am Nabriva Therapeutics EPS in-line, beats on revenue seekingalpha.com Nov 6, 2020 5:05 am
Nabriva Soars on Agreement With Merck to Distribute Sivextro finance.yahoo.com Dec 11, 2020 12:00 pm
Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More finance.yahoo.com Dec 11, 2020 11:00 am
Nabriva Shares Rip Higher Following FDA Nod For Novel Antibiotic finance.yahoo.com Dec 11, 2020 8:36 am
The Daily Biotech Pulse: 2 IPOs, Nabriva Pneumonia Drug Gets Canadian Regulatory Nod, PhaseBio Doses First COVID-19 Trial Patient finance.yahoo.com Dec 11, 2020 7:41 am
The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contepo Resubmission finance.yahoo.com Dec 11, 2020 7:33 am Key Persons CEO : Ted C. Schroeder CFO : Gary Sender Talk about Nabriva Therapeutics PLC below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature. Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
If you want to help pay for server cost or for improving this tool. You can send it via Paypal . More features coming soon :)
Buy on Amazon Technical analysis is a collection of techniques designed to help you make trading decisions in securities markets. Technical Analysis For Dummies helps you take a hard-headed look at what securities prices are actually doing rather than what economists or analysts say they should be doing, giving you the know-how to use that data to decide whether to buy or sell individual securities.
A simple, straightforward guide to the fundamentals of technical analysis